10-Q: Sanara MedTech Inc. Reports Third Quarter 2024 Results, Revenue Up 35%

Sanara MedTech Inc. saw a 35% increase in revenue year-over-year for the third quarter of 2024, driven by strong sales of soft tissue repair products.

Summary

• Sanara MedTech Inc. reported a net revenue of $21.7 million for the third quarter of 2024, a 35% increase compared to $16.0 million in the same period of 2023.
• The company's gross profit for the quarter was $19.7 million, up from $14.3 million in the prior year, representing a 38% increase.
• Operating expenses totaled $21.6 million, compared to $15.2 million in the third quarter of 2023.
• The company reported a net loss of $2.9 million for the quarter, compared to a net loss of $1.1 million in the third quarter of 2023.
• For the nine months ended September 30, 2024, net revenue was $60.4 million, a 28% increase from $47.3 million in the same period of 2023.
• The company's gross profit for the nine months was $54.5 million, up from $41.2 million in the prior year, representing a 32% increase.
• Operating expenses for the nine months totaled $60.8 million, compared to $45.2 million in the same period of 2023.
• The net loss for the nine months ended September 30, 2024 was $8.2 million, compared to a net loss of $4.2 million in the same period of 2023.
• The company has changed its reportable segments to Sanara Surgical and Tissue Health Plus (THP).
• Sanara Surgical primarily markets and sells soft tissue repair and bone fusion products.
• THP is focused on value-based wound care services and is expected to commercially launch in mid-2025.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While revenue growth and gross margins are strong, the company is still operating at a loss and has significant operating expenses. The strategic investment in THP and the secured term loan are positive, but the company's future performance is dependent on the success of these initiatives.

Positives

• Revenue growth was strong, with a 35% increase in the third quarter and a 28% increase for the nine months ended September 30, 2024.
• Gross profit margins improved to 91% for the third quarter and 90% for the nine months ended September 30, 2024.
• The company secured a significant term loan, providing additional capital for growth.
• The company made a strategic investment in ChemoMouthpiece, LLC, expanding its product portfolio.
• The company's cash position has improved significantly.

Negatives

• The company reported a net loss of $2.9 million for the third quarter and $8.2 million for the nine months ended September 30, 2024.
• Operating expenses increased significantly, primarily due to the buildout of the THP platform and higher sales and marketing costs.
• The company's THP segment is still in development and is not yet generating revenue.

Risks

• The company's indebtedness could adversely affect its financial condition and prevent it from fulfilling its obligations.
• The company's outstanding indebtedness is subject to certain operating and financial covenants that restrict its business and financing activities.
• The company's THP segment is still in development and is not yet generating revenue, which could impact future financial performance.
• The company is subject to intense competition in the markets in which it operates.
• The company's ability to develop and commercialize new products and products under development is subject to risk.

Future Outlook

The company plans to commercially launch the THP program in mid-2025 and expects to continue its investment in the THP strategy. The company anticipates that THP's customer contracts will have three-to-five-year terms and incorporate a mix of value-based pricing methodologies. The company expects its future needs for cash to include the funding of its additional investment in THP, potential acquisitions, further developing its products, services and technologies pipeline and clinical studies, expanding its sales force, repayment of debt as it becomes due and for general corporate purposes.

Management Comments

• The company is continually seeking to expand its offerings for patients requiring treatments across the entire continuum of care in the United States.
• The company plans to offer a first of its kind value-based wound care program to payers and risk-bearing entities through THP.
• The company believes its cash on hand, when combined with expected cash flows from operations and available proceeds from the CRG Term Loan, will be sufficient to fund its growth strategy and to meet its anticipated operating expenses and capital expenditures for at least the next twelve months.

Industry Context

The company operates in the medical technology sector, specifically focusing on surgical, chronic wound, and skincare markets. The company's strategy to expand its offerings across the continuum of care aligns with the industry trend of providing comprehensive solutions. The company's focus on value-based care through THP is also in line with the industry's shift towards cost-effective healthcare solutions.

Comparison to Industry Standards

• Sanara's revenue growth of 35% in Q3 2024 is strong compared to the average growth rate of medical device companies, which typically ranges from 5% to 15%.
• The company's gross margin of 91% in Q3 2024 is significantly higher than the industry average, which is typically between 60% and 70%.
• The company's operating expenses are higher than some of its peers, primarily due to the buildout of the THP platform and higher sales and marketing costs.
• The company's net loss is a concern, but it is not uncommon for growth-stage medical device companies to operate at a loss while investing in expansion and product development.
• Compared to companies like Smith+Nephew and Integra LifeSciences, Sanara is smaller but has a higher growth rate and gross margin.
• The company's investment in THP is a unique approach compared to many of its competitors, which are primarily focused on product sales.

Related Party Transactions

• The company had an exclusive, world-wide sublicense to distribute CellerateRX Surgical products from an affiliate of Catalyst, CGI Cellerate RX.
• The company has product license agreements with Rochal Industries, LLC.
• The company has a consulting agreement with Ann Beal Salamone.
• The company has a Transaction Advisory Services Agreement with Catalyst.

Stakeholder Impact

• Shareholders may be concerned about the company's net losses, but encouraged by the revenue growth and strategic investments.
• Employees may be impacted by the company's growth and expansion plans.
• Customers may benefit from the company's expanded product offerings and value-based care programs.
• Suppliers may see increased demand for their products as the company grows.
• Creditors may be impacted by the company's debt obligations and financial performance.

Next Steps

• The company plans to commercially launch the THP program in mid-2025.
• The company will continue to invest in the THP strategy.
• The company will continue to develop its products, services and technologies pipeline.
• The company will continue to expand its sales force.

Key Dates

Keywords

medical technology, surgical, wound care, soft tissue repair, bone fusion, revenue growth, EBITDA, term loan, acquisition, Tissue Health Plus, CellerateRX Surgical, BIASURGE, ChemoMouthpiece